Literature DB >> 24826915

REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy.

Maira J Maturana1, Cláudia Pudell, Adriano D S Targa, Laís S Rodrigues, Ana Carolina D Noseda, Mariana H Fortes, Patrícia Dos Santos, Cláudio Da Cunha, Sílvio M Zanata, Anete C Ferraz, Marcelo M S Lima.   

Abstract

There is compelling evidence that sleep deprivation (SD) is an effective strategy in promoting antidepressant effects in humans, whereas few studies were performed in relevant animal models of depression. Acute administration of antidepressants in humans and rats generates a quite similar effect, i.e., suppression of rapid eye movement (REM) sleep. Then, we decided to investigate the neurochemical alterations generated by a protocol of rapid eye movement sleep deprivation (REMSD) in the notably known animal model of depression induced by the bilateral olfactory bulbectomy (OBX). REMSD triggered antidepressant mechanisms such as the increment of brain-derived neurotrophic factor (BDNF) levels, within the substantia nigra pars compacta (SNpc), which were strongly correlated to the swimming time (r = 0.83; P < 0.0001) and hippocampal serotonin (5-HT) content (r = 0.66; P = 0.004). Moreover, there was a strong correlation between swimming time and hippocampal 5-HT levels (r = 0.70; P = 0.003), strengthen the notion of an antidepressant effect associated to REMSD in the OBX rats. In addition, REMSD robustly attenuated the hippocampal 5-HT deficiency produced by the OBX procedure. Regarding the rebound (REB) period, we observed the occurrence of a sustained antidepressant effect, indicated mainly by the swimming and climbing times which could be explained by the maintenance of the increased nigral BDNF expression. Hence, hippocampal 5-HT levels remained enhanced in the OBX group after this period. We suggested that the neurochemical complexity inflicted by the OBX model, counteracted by REMSD, is directly correlated to the nigral BDNF expression and hippocampal 5-HT levels. The present findings provide new information regarding the antidepressant mechanisms triggered by REMSD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24826915     DOI: 10.1007/s12035-014-8721-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  54 in total

1.  Effects of ipsapirone, a 5-HT1A agonist, on sleep/wakefulness cycles: probable post-synaptic action.

Authors: 
Journal:  J Sleep Res       Date:  1993-06       Impact factor: 3.981

2.  Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats.

Authors:  Megan E Breuer; Lucianne Groenink; Ronald S Oosting; Herman G M Westenberg; Berend Olivier
Journal:  Biol Psychiatry       Date:  2006-12-04       Impact factor: 13.382

3.  Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.

Authors:  Mariana B Proença; Patrícia A Dombrowski; Claudio Da Cunha; Luana Fischer; Anete C Ferraz; Marcelo M S Lima
Journal:  Neuropharmacology       Date:  2013-09-04       Impact factor: 5.250

4.  Can repetitive transcranial magnetic stimulation prolong the antidepressant effects of sleep deprivation?

Authors:  Peter M Kreuzer; Berthold Langguth; Martin Schecklmann; Peter Eichhammer; Goeran Hajak; Michael Landgrebe
Journal:  Brain Stimul       Date:  2011-03-23       Impact factor: 8.955

5.  Neural correlates of sleepiness induced by catecholamine depletion.

Authors:  Noah Meyers; Stephen Fromm; David A Luckenbaugh; Wayne C Drevets; Gregor Hasler
Journal:  Psychiatry Res       Date:  2011-08-27       Impact factor: 3.222

6.  Antidepressant properties of rotigotine in experimental models of depression.

Authors:  Valerie Bertaina-Anglade; Christophe Drieu La Rochelle; Dieter K A Scheller
Journal:  Eur J Pharmacol       Date:  2006-07-22       Impact factor: 4.432

Review 7.  Therapeutic use of sleep deprivation in depression.

Authors:  Henner Giedke; Frank Schwärzler
Journal:  Sleep Med Rev       Date:  2002-10       Impact factor: 11.609

8.  Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation.

Authors:  Marcelo M S Lima; Monica L Andersen; Angela B Reksidler; Andressa Silva; Adriano Zager; Sílvio M Zanata; Maria A B F Vital; Sergio Tufik
Journal:  Behav Brain Res       Date:  2007-12-08       Impact factor: 3.332

9.  Desipramine-induced increase in norepinephrine transporter mRNA is not mediated via alpha 2 receptors.

Authors:  M M Shores; P Szot; R C Veith
Journal:  Brain Res Mol Brain Res       Date:  1994-12

10.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382

View more
  8 in total

1.  Role of endothelin receptor type A on catecholamine regulation in the olfactory bulb of DOCA-salt hypertensive rats: Hemodynamic implications.

Authors:  María J Guil; Mercedes I Schöller; Luis R Cassinotti; Vinicia C Biancardi; Soledad Pitra; Liliana G Bianciotti; Javier E Stern; Marcelo S Vatta
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-08-06       Impact factor: 5.187

Review 2.  Modulating role of serotonergic signaling in sleep and memory.

Authors:  Salar Vaseghi; Shirin Arjmandi-Rad; Maliheh Eskandari; Mahshid Ebrahimnejad; Gita Kholghi; Mohammad-Reza Zarrindast
Journal:  Pharmacol Rep       Date:  2021-11-06       Impact factor: 3.024

Review 3.  The Brain-Derived Neurotrophic Factor: Missing Link Between Sleep Deprivation, Insomnia, and Depression.

Authors:  Maryam Rahmani; Farzaneh Rahmani; Nima Rezaei
Journal:  Neurochem Res       Date:  2019-11-28       Impact factor: 3.996

4.  Repeated exposure to conditioned fear stress increases anxiety and delays sleep recovery following exposure to an acute traumatic stressor.

Authors:  Benjamin N Greenwood; Robert S Thompson; Mark R Opp; Monika Fleshner
Journal:  Front Psychiatry       Date:  2014-10-20       Impact factor: 4.157

5.  Chronic sleep restriction in the rotenone Parkinson's disease model in rats reveals peripheral early-phase biomarkers.

Authors:  Juliane Fagotti; Adriano D S Targa; Lais S Rodrigues; Ana Carolina D Noseda; Flávia W C Dorieux; Franciele F Scarante; Jessica L Ilkiw; Fernando M Louzada; Namrata R Chowdhury; Daan R van der Veen; Benita Middleton; Jeroen L A Pennings; Jonathan R Swann; Debra J Skene; Marcelo M S Lima
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

6.  Perspectives for the association between olfactory disturbances and depression in Parkinson's disease.

Authors:  Jessica L Ilkiw; Marcelo M S Lima
Journal:  Neural Regen Res       Date:  2019-04       Impact factor: 5.135

7.  Urinary Metabolomic Study of Chlorogenic Acid in a Rat Model of Chronic Sleep Deprivation Using Gas Chromatography-Mass Spectrometry.

Authors:  Wei-Ni Ma; Ming-Mei Zhou; Xiao-Jun Gou; Le Zhao; Fang Cen; Ying Xu; Hong-Yi Shen
Journal:  Int J Genomics       Date:  2018-02-11       Impact factor: 2.326

8.  Rapid Eye Movement Sleep Deprivation Combined With Fluoxetine Protects Against Depression-Induced Damage and Apoptosis in Rat Hippocampi via A1 Adenosine Receptor.

Authors:  Xuan Ju; Shengdong Wang; Pan Yan; Chunyan Zhu; Xiwen Hu; Jiezheng Dong; Zhonglin Tan
Journal:  Front Psychiatry       Date:  2021-07-16       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.